Ellen Elizabeth Romich

Ellen Romich practices at Perelman Center for Advanced Medicine in Philadelphia, Pennsylvania.

Ellen Romich's NPI, 1619437308, was assigned on March 20, 2019. Ellen Romich holds Pennsylvania license MD484793.

Ellen Romich's primary practice is Perelman Center for Advanced Medicine, at 3400 Civic Center Blvd, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-2454.

Ellen Romich's primary practice is Perelman Center for Advanced Medicine in Philadelphia, Pennsylvania. Ellen Romich is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Ellen Romich to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Ellen Romich practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Ellen Romich's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Ellen Romich is licensed in Pennsylvania.

CMS data shows 22 Medicare services from Ellen Romich across 1 procedure code in 2024, for 17 Medicare patients. Medicare paid $292 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 17 Medicare patients who saw Ellen Romich in 2024. 75% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 1.24, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Ellen Romich's median patient age at 58, with 72% women.

In 2024, Ellen Romich wrote 196 Medicare Part D claims for 30 patients. 83% of them were for generic drugs. CMS names the drug for 121 of them, across 5 drugs with 11 or more claims each, at $2,828 in total drug cost.

Ellen Romich accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Ellen Romich as offering telehealth.

CMS Open Payments shows 1 general payment to Ellen Romich from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $53. It also lists 1 research payment totaling $330 in 2024.